BEDFORD, Mass.--(BUSINESS WIRE)--May 2, 2019--
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company
focused on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced that it will report first quarter ended March 31, 2019
financial results on Friday, May 10, 2019. Following distribution of the
earnings release via wire services, the Ocular Therapeutix management
team will host a live conference call and webcast at 8:30 a.m. Eastern
Time to review the Company’s financial results and provide a general
business update.
The live webcast can be accessed by visiting the Investors section of
the Company’s website at investors.ocutx.com.
Please connect at least 15 minutes prior to the live webcast to ensure
adequate time for any software download that may be needed to access the
webcast. Alternatively, please call (844) 464-3934 (U.S.) or (765)
507-2620 (International) to listen to the live conference call. The
conference ID number for the live call will be 9580369. An archive of
the webcast will be available until August 12, 2019 on the Company’s
website.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
formulation, development, and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary
bioresorbable hydrogel-based formulation technology. Ocular
Therapeutix’s first commercial drug product, DEXTENZA®, is FDA-approved
for the treatment of ocular pain following ophthalmic surgery. OTX-TP
(intracanalicular travoprost insert) is an intracanalicular insert in
Phase 3 clinical development for the reduction of intraocular pressure
in patients with primary open-angle glaucoma and ocular hypertension.
The Company’s earlier stage assets include OTX-TIC, an extended-delivery
intracameral travoprost implant for the reduction of intraocular
pressure in patients with glaucoma and ocular hypertension, as well as
sustained release intravitreal implants for the treatment of retinal
diseases. These intravitreal implants include OTX-TKI, containing a
tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron,
OTX-IVT, an extended-delivery protein-based anti-vascular endothelial
growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure®
Sealant, is FDA-approved to seal corneal incisions following cataract
surgery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190502005197/en/
Source: Ocular Therapeutix
Investors
Ocular Therapeutix
Donald Notman
Chief
Financial Officer
dnotman@ocutx.com
or
Westwicke
Partners
Chris Brinzey
Managing Director
chris.brinzey@westwicke.com
Media
Ocular
Therapeutix
Scott Corning
Senior Vice President, Commercial
scorning@ocutx.com